Ocata Therapeutics, Inc. , a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced that it has received notice that the NASDAQ Listing Qualifications Department has approved its application to list the Company's common stock on the NASDAQ Global Market, effective with the opening of trading today, February 26, 2015, under the ticker symbol "OCAT". "This is a significant step in the Company's evolution and crucial to our long-term corporate strategy," stated Ted Myles, Chief Operating Officer and Chief Financial Officer, of Ocata.
http://ift.tt/1vCkKAN
http://ift.tt/1vCkKAN
No comments:
Post a Comment